

## ANZMTG Scientific Research and Annual General Meeting

Friday 25 November 2011 from 10:30am to 5:30pm

Lecture Theatre, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne

<b>Scientific Meeting– all members welcome</b>		
<b>Agenda – Arrive at 10am / Commence meeting promptly at 10:30am</b>	<b>Speaker</b>	<b>Time</b>
Introduction and welcome	<i>John Thompson</i>	10:30am
<b>Current Melanoma Research Presentations</b>		<b>10:30-12:30pm</b>
1. Recent advances in dermatology	<i>John Kelly</i>	10:30-10:40am
2. Surgical oncology update – advances in melanoma surgery	<i>John Thompson</i>	10:40-10:50am
3. Current radiotherapy research in respect to melanoma treatment	<i>Bryan Burmeister</i>	10:50-11:00am
4. Personalised medicine –Targeted therapies	<i>Grant McArthur</i>	11:00–11:15am
5. Immunology and melanoma	<i>Jonathon Cebon</i>	11:15–11:30am
6. Consumers Input – Q&A	<i>Consumer Representative</i>	11:30-11:45am
7. The Melbourne Melanoma Project Melanoma Database Experience	<i>Anne Woollett</i>	11:45-12:00pm
8. Discussion	<i>All</i>	12:00-12:30pm
<b>Lunch and ANZMTG AGM (see agenda)</b>		<b>ANZMTG full members 12:30-1:30pm</b>
<b>Presentation of New Research Proposals</b>		<b>1:30-3:45pm</b>
1. A multicentre randomised clinical trial evaluating ilio-inguinal and inguinal dissection for patients with metastatic melanoma	<i>Andrew Spillane</i>	1:30-1:45pm
2. Radiotherapy followed by selective nodal dissection for bulky and/or inoperable nodal melanoma	<i>Matthew Foote</i>	1:45–2:00pm
3. Paediatric melanoma database proposal	<i>Sian Fairbank</i>	2:00-2:15pm
4. How can we conduct combined therapy trials efficiently?	<i>Georgina Long</i>	2:15-2:20pm
5. Phase I study combining BRAF inhibitor with radiation therapy for the treatment of subcutaneous metastases from BRAF mutant metastatic melanoma	<i>Gerald Fogarty / Georgina Long</i>	2:20-2:30pm
6. Prospective study evaluating combination therapy of BCG vaccine and Ipilimumab for patients with stage III/IV disease	<i>Jonathan Cebon</i>	2:30-2:45pm
7. Prospective non-comparative trial examining safety & efficacy of combining Ipilimumab and palliative radiotherapy in patients with metastatic melanoma	<i>Kathy Pope</i>	2:45-3:00pm
8. 2 proposals (i) Melanoma vaccine timed immunotherapy trial & (ii) ILI common data set collection	<i>Brendon Coventry</i>	3:00-3:15pm
9. A multicentre randomised clinical trial evaluating adjuvant RT vs imiquimod vs observation for high risk lentigo maligna post resection	<i>John Kelly / Jeremy Ruben</i>	3:15-3:20pm
10. A population study investigating the incidence of advanced melanoma in WA - a prospective study	<i>Carolyn Williams</i>	3:20-3:35pm
11. Quality of life in melanoma proposal	<i>Donna Milne</i>	3:35-3:45pm

<b>Afternoon tea</b>	All	3:45–4:00pm
<b>Agenda</b>	<b>Speaker</b>	<b>Time</b>
<b>Current ANZMTG Clinical Trials Presentations</b>	<i>Chairs: John Thompson, Michael Henderson &amp; Ben Brady</i>	<b>4:00-5:00pm</b>
1. Melanoma Quality of Life activities and update; ANZMTG 01.09RP Improving Quality of Life measurement for melanoma patients: Validity and reliability study of QoL instruments in a NSW population (MELQOL) & EORTC Melanoma Module (MELMOD)	<i>Julie Winstanley</i>	
2. ANZMTG 01.02 A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma (Adjuvant Rx)	<i>Michael Henderson</i>	
3. ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial (WBRT Mel)	<i>Gerald Fogarty</i>	
4. ANZMTG 01.07 WBRT Mel – Health economic evaluation of WBRT Substudy	<i>Rachael Morton</i>	
5. ANZMTG 01.09 Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial (Mel-D)	<i>Rachael Morton</i>	
6. ANZMTG 02.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2)	<i>Matthew Foote</i>	
7. JWCI; A Phase III, Randomized Trial of Surgical Resection with BCG versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma (Stage IV protocol)	<i>John Thompson</i>	
8. UK Melanoma Study Group; <u>Melanoma Margins Trial</u> (MelMarT)	<i>John Thompson</i>	
Current Projects not presented:		
9. ANZMTG 01.10 Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic Melanoma (CARPETS)		
<b>Consumer Discussion – Direction of research priorities</b>	<i>Consumer Representative</i>	5:00-5:15pm
<b>Concluding remarks</b>	<i>Michael Henderson</i>	5:15-5:30pm
<b>Meeting close at 5:30pm</b>		

**ANZMTG Annual General Meeting 2011 – all full members welcome**

<b>Agenda – Commence Meeting at 12:40pm</b>		<b>Speaker</b>	<b>Attachments</b>
<b>1</b>	<b>Greetings and Apologies</b>	<i>Prof J. Thompson</i>	
<b>2</b>	<b>Review and Approve Minutes of Previous Meeting (6Nov2010)</b>	<i>Prof J. Thompson</i>	2010 AGM Minutes (1)
<b>3</b>	<b>Chairman’s report</b>	<i>Prof J. Thompson</i>	Chairman’s report (2)
<b>4</b>	<b>Finance report</b>	<i>Libby Paton</i>	Financial statement 10/11 (3)
<b>5</b>	<b>Operations report</b>	<i>Libby Paton</i>	Clinical Trials Summary (4) ANZMTG Membership summary (5)
<b>6</b>	<b>Terms of Reference and Nomination Process for the Executive Committee</b>	<i>Prof J. Thompson</i>	
<b>7</b>	<b>Other business</b>	<i>Prof J. Thompson</i>	
<b>8</b>	<b>Meeting Close at 12:50pm</b>		